Background: Children are not small adults: their anatomical proportions, physiological responses, metabolic determinants of stone disease, behavioral requirements during procedures, and — critically — the long-term implications of any renal parenchymal injury on a still-developing kidney demand a distinctly tailored approach to extracorporeal shock wave lithotripsy (ESWL). First applied to children by Newman et al. in 1986, ESWL is now established as first-line treatment for most upper urinary tract stones ≤ 15–20 mm in the pediatric population. The pediatric urinary system confers biological advantages — reduced skin-to-stone distance, more distensible ureters, and lower stone density — that in some respects make children better ESWL candidates than adults. However, the universal 100% high-recurrence-risk classification of all pediatric stone patients (EAU 2024; AUA 2025), the mandatory anesthesia requirement, the heightened radiosensitivity of children, and the ongoing question of cumulative shock wave effects on the growing kidney collectively demand a more deliberate and protocol-driven approach than in adult lithotripsy practice.
Objectives: This article provides a comprehensive, evidence-based framework for ESWL in children, addressing: the epidemiology and stone composition profile of pediatric urolithiasis; efficacy data including predictors of success; the absolute anesthesia imperative and validated sedation protocols; the ALARA radiation protection principle applied to targeting and follow-up imaging; the short- and long-term renal safety evidence for the growing kidney; the critical distinction between clinically insignificant residual fragments in adults versus children; and a practical clinical protocol for pre-procedure assessment, intraoperative technique, post-procedure management, and modality selection.
Methods: A structured narrative review was conducted incorporating the Lu et al. systematic review and meta-analysis of pediatric ESWL efficacy (Urolithiasis 2015; PMID: 25721456); the Hasaneen et al. 500-case series (PMID: 22350835); the El-Assmy et al. adult-versus-child comparative study (PMID: 18727616); a 2026 Frontiers in Pediatrics randomized comparison of stepwise energy escalation versus fixed-energy protocols in 81 children (doi: 10.3389/fped.2026.1736104); the Cevik et al. 10-year anesthesia retrospective analysis of 408 ESWL sessions in 251 children (PMID: 28642966); the Griffin et al. 20-year long-term safety series (PMID: 20400129); the Vlajković et al. GFR trajectory study; the Swiss long-term cohort of 70 pediatric patients; the Akin and Yucel narrative review of 3,000 articles (PMC: PMC4011895); the Afshar et al. residual fragment outcome study; and the 2024 EAU and 2025 AUA urolithiasis guidelines.
Results: Published stone-free rates for pediatric ESWL range from 67–93% at three months, with stones < 10 mm achieving significantly higher rates than larger stones (pooled RR 1.14; 95% CI 1.07–1.21; p < 0.001) and proximal ureteric stones outperforming mid/distal locations (RR 1.077; p = 0.036). Children achieve equivalent stone-free rates to adults while requiring significantly fewer and lower-energy shock waves (p < 0.01), confirming the fundamental advantage of reduced body habitus. A 2026 Frontiers RCT demonstrated that stepwise energy escalation achieves significantly higher first-session stone-free rates (73.2% vs 55.0%) and 3-month rates (95.1% vs 87.5%) compared to fixed-energy protocols without additional morbidity. All children up to approximately 14 years require general anesthesia or deep procedural sedation; ketamine-midazolam combination sedation was validated across 408 ESWL sessions in 251 children aged 7 months to 14 years with no severe complications. Long-term renal safety is supported by four decades of follow-up data: the Griffin 20-year series found no permanent renal scarring or long-term renal function loss; Vlajković et al. demonstrated complete GFR recovery by 3 months after a transient post-ESWL reduction; the Swiss 70-patient cohort confirmed no hypertension, no diabetes, and no impaired renal growth attributable to ESWL. However, residual fragments deemed clinically insignificant in adults carry a high progression risk in children: 69% of residual fragments ≤ 5 mm and 33% of fragments < 3 mm showed increasing stone mass on follow-up, making complete clearance — not fragment reduction — the correct treatment endpoint. Cystine stones are an absolute ESWL contraindication in children and require redirection to ureteroscopy with holmium laser lithotripsy.
Conclusions: ESWL is a safe, effective, and non-invasive first-line treatment for upper urinary tract stones ≤ 15 mm in children, with a long-term safety record that does not support permanent harm to the growing kidney when protocol-optimized. The non-negotiable pillars of safe pediatric ESWL practice are: general anesthesia or deep procedural sedation for every session; ultrasound-guided targeting to minimize radiation exposure (ALARA); shock wave rate reduction to 60/min or below; mandatory stepwise energy escalation; a maximum of three sessions before modality reassessment; complete metabolic evaluation in all children (EAU 2024 guideline); and a stringent stone-free rate standard at three months that treats any fragment > 3–4 mm as treatment failure requiring active management. Ureteroscopy under a single anesthetic should be preferred over multiple ESWL sessions for cystine stones, stones > 15–20 mm, and cases of failed ESWL, to minimize cumulative anesthetic burden, radiation exposure, and renal parenchymal injury.